uniQure N.V. (NASDAQ:QURE) Files An 8-K Other Events

ME Staff 8-k
-
0

uniQure N.V. (NASDAQ:QURE) Files An 8-K Other Events
Item 8.01. Other Events

In connection with the filing of the definitive proxy on Schedule 14A on May 1, 2017, in which the shareholders of uniQure N.V. (the “Company”) have been asked to approve the Dutch statutory annual accounts for the year ended December 31, 2016 at the Company’s 2017 annual general meeting of shareholders, the Company has filed its Dutch statutory annual accounts on Exhibit 99.1 to this Current Report on Form 8-K.

As a public limited liability corporation (“namenslooze vennopschaap”) incorporated under the laws of the Netherlands, the Company is required by both Dutch law and its Articles of Association to prepare the Dutch statutory annual accounts and submit them to its shareholders for confirmation and adoption. The 2016 Dutch statutory annual accounts differ from the consolidated financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, that were prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), and filed with the SEC. The 2016 Dutch statutory annual accounts contain some disclosures that are not required under U.S. GAAP and not contained in our 2016 Annual Report on Form 10-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Dutch statutory annual report of uniQure N.V. for the year ended December 31, 2016, as made available to the Company’s shareholders on or about May 1, 2016.


About uniQure N.V. (NASDAQ:QURE)

uniQure N.V. (uniQure) is a gene therapy company. The Company is engaged in developing single treatments with curative results for patients suffering from genetic and other severe diseases. The Company is advancing a focused pipeline of gene therapies that have been developed both internally and through partnerships. The Company’s product candidates include AMT-060 for Hemophilia B, AMT-130 for Huntington’s disease, S100A1 for congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). uniQure has established clinical proof-of-concept in its lead indication, hemophilia B and has achieved pre-clinical, proof-of-concept in Huntington’s disease. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.

uniQure N.V. (NASDAQ:QURE) Recent Trading Information

uniQure N.V. (NASDAQ:QURE) closed its last trading session up +0.10 at 5.46 with 105,698 shares trading hands.